Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

126.84 +0.20 (+0.16%)
Streaming Delayed Price Updated: 11:26 AM EDT, Aug 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
UK Drug Pricing Talks Collapse, Drugmakers Reject Offer Citing 'Uncompetitive' System
UK drug pricing talks collapsed after the government and pharma firms failed to agree on National Health Service rebates. 
Via Benzinga
Novartis AG-Sponsored ADR (NYSE:NVS) – A Top Dividend Stock with Strong Yield and Financial Stability
Novartis (NVS) offers a strong 3.55% dividend yield, backed by consistent payouts, solid profitability, and financial health—ideal for stable income investing. 
Via Chartmill
Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm
These companies have successfully navigated similar obstacles before. 
Via The Motley Fool
Topics Intellectual Property
How Is The Market Feeling About Novartis?
 
Via Benzinga
2 Dividend Stocks to Buy and Hold
These stocks look like they can weather almost any storm. 
Via The Motley Fool
Topics Artificial Intelligence Cannabis Government
P/E Ratio Insights for Novartis
 
Via Benzinga
Novartis Rides Bullish Retail Mood, Roche Faces Gloom Amid Swiss-US Trade Concerns
Via Stocktwits
Novartis Reportedly Eyeing To Acquire Avidity Biosciences: But Retail Expects Management To Sell Only At Significant Premium
Via Stocktwits
NOVARTIS AG-SPONSORED ADR (NYSE:NVS) Emerges as a Top Pick for Value Investors with Strong Fundamentals and Attractive Valuation
Novartis AG-SPONSORED ADR (NVS) is a top pick for value investors, offering solid fundamentals, strong profitability, and a 3.76% dividend yield, all at an attractive valuation. 
Via Chartmill
Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate
Vor Bio shares climb as RemeGen's Phase 3 study in China shows telitacicept improves disease activity in primary Sjögren's disease. 
Via Benzinga
Novartis Sees Hope In Reducing Lifelong Treatment Burden For Autoimmune Blood Disorder
Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 immune thrombocytopenia trial. 
Via Benzinga
This Stock Has Tumbled 50% In One Year, Gets A Price Target Cut Today – But Retail Believes $400-450 Is A Good Entry Point
Truist, however, kept a ‘Buy’ rating on the shares. 
Via Stocktwits
Novartis Drug Shows Improvement In Sjögren's Disease In Late-Stage Trials: Analyst Deems Data Positive For Zura Bio As Well
Novartis now sees the potential for the drug to become the first and only targeted treatment approved for patients with the disease. 
Via Stocktwits
Novartis' Investigational Drug Aces Two Pivotal Trials For Chronic Disease Impacting Tears, Saliva
Novartis' ianalumab showed significant disease activity improvement in two Phase 3 Sjögren's trials, supporting plans for global health authority filings. 
Via Benzinga
Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%
Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales outlook after Q2 beat. 
Via Benzinga
2 Brilliant Vanguard Index Funds to Buy With $1,000 in August and Hold Forever
These Vanguard index funds offer diversified exposure to many of the most influential stocks in the world. 
Via The Motley Fool
Topics ETFs
PTCT Earnings Beat but Sales Drop 4%
Via The Motley Fool
Topics Earnings
Monte Rosa (GLUE) Q2 Revenue Jumps 394%
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
Schrödinger (SDGR) Q2 2025 Earnings Transcript
Via The Motley Fool
Novo Nordisk Commits To Advancing Prothena Corp-Developed Drug Into Late Stage Trial: Retail Turns Hopeful
Coramitug was initially developed by Prothena and was acquired by Novo Nordisk in July 2021. 
Via Stocktwits
Topics Earnings
Avidity Biosciences Rockets As Novartis Reportedly Mulls A Takeover Deal
The company is focused on treatments for forms of muscular dystrophy. 
Via Investor's Business Daily
Pfizer's Ascent Signals Broader Health Sector Resilience Amidst Innovation Wave
In a notable shift, shares of Pfizer (NYSE: PFE) have recently edged higher, reflecting a burgeoning strength within the broader health sector. This uptick signals a renewed investor confidence in the... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch
Via Stocktwits
Topics Government
3 Pharma Stocks That Aren't Sweating the Coming 200% Drug Tariffs
US President Trump imposed 200% tariff on pharmaceuticals affecting US drug prices and supply chain, but analysts say it may not happen soon. 
Via Benzinga
Topics Economy Government World Trade
Sarepta Gets Thumbs Down From Regulators Regarding Elevidys Gene Therapy
Sarepta and Roche face a regulatory setback as the EMA's CHMP issues a negative opinion on Elevidys for Duchenne muscular dystrophy patients. 
Via Benzinga
U.S. Current-Account Deficit Widens to $450 Billion Amid Trade Imbalances and Energy Imports
The United States current-account deficit expanded sharply to $450 billion in the first half of 2025, marking a renewed widening of the country's financial shortfall with the rest of the world. This... 
Via MarketMinute
Topics Artificial Intelligence Economy Supply Chain
NOVARTIS AG-SPONSORED ADR (NYSE:NVS): A Top Dividend Stock with Strong Profitability and Financial Stability
NOVARTIS AG (NVS) is a top dividend stock with a 3.76% yield, strong profitability, and financial stability, making it ideal for income-focused investors. 
Via Chartmill
The Hits Keep Coming For Sarepta. Why Its Latest Setback Creates A 'Dangerous Precedent' For Gene Therapies.
Sarepta stock is now trading at a nine-year low as the debacle with its gene therapy, Elevidys, continues. 
Via Investor's Business Daily
Topics Death Workforce
Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US
AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs. 
Via Benzinga
Topics Government
Highest Ever for This International Stock ETF -- But Analysts Say It Has Room to Run
Via The Motley Fool
Topics ETFs World Trade
< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.